Jonathan Haroon
Jonathan Haroon has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Kennedy Mahdavi
4 shared publications- Margaret A. Zielinski
The Regenesis Project, 2811 Wilshire Blvd, Suite 790, Los Angeles, CA, 90403, USA
4 shared publications - Barshen Habelhah
Neurological Associates ‐ The Interventional Group Santa Monica CA USA
3 shared publications Sheldon Jordan
3 shared publications- Sheldon Jordan
Neurological Associates of West Los Angeles
3 shared publications - Taylor Kuhn
Department of Psychiatry and Behavioral Sciences University of California Los Angeles California United States of America
3 shared publications
Latest Publications
- Open Access
- 26 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (30) , e39027
A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias
Background: Alzheimer’s disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD. Methods: In this phase 2, open-label study, 23 patients with mild cognitive impairment or mild dementia received 20-mg oral NE3107 twice daily for 3 months. Primary endpoints assessed changes from baseline in neurophysiological health and oxidative stress (glutathione level) using advanced neuroimaging analyses. Secondary endpoints evaluated changes from baseline in neuropsychological health using cognitive assessments, including the 11-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment, Clinical Dementia Rating, Quick Dementia Rating Scale, Alzheimer’s Disease Composite Score, and Global Rating of Change (GRC). Exploratory endpoints assessed changes from baseline in neuroinflammation biomarkers (tumor necrosis factor alpha, TNF-α) and AD (amyloid beta and phosphorylated tau [P-tau]). Results: NE3107 was associated with clinician-rated improvements in cerebral blood flow and functional connectivity within the brain. In patients with MMSE ≥ 20 (mild cognitive impairment to mild AD; n = 17), NE3107 was associated with directional, but statistically nonsignificant, changes in brain glutathione levels, along with statistically significant improvements in ADAS-Cog11 (P = .017), Clinical Dementia Rating (P = .042), Quick Dementia Rating Scale (P = .002), Alzheimer’s Disease Composite Score (P = .0094), and clinician-rated GRC (P < .001), as well as in cerebrospinal fluid P-tau levels (P = .034) and P-tau:amyloid beta 42 ratio (P = .04). Biomarker analyses also demonstrated directional, but statistically non-significant, changes in plasma TNF-α, consistent with the expected mechanism of NE3107. Importantly, we observed a statistically significant correlation (r = 0.59) between improvements in TNF-α levels and ADAS-Cog11 scores (P = .026) in patients with baseline MMSE ≥ 20. Conclusion: Our results indicate that in this study NE3107 was associated with what appear to be positive neurophysiological and neuropsychological findings, as well as evidence of improvement in biomarkers associated with neuroinflammation and AD in patients diagnosed with dementia. Our findings are consistent with previous preclinical and clinical observations and highlight a central role of neuroinflammation in AD pathogenesis.
- 26 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (30) , e39027
Open AccessA phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias
Background: Alzheimer’s disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD. Methods: In this phase 2, open-label study, 23 patients with mild cognitive impairment or mild dementia received 20-mg oral NE3107 twice daily for 3 months. Primary endpoints assessed changes from baseline in neurophysiological health and oxidative stress (glutathione level) using advanced neuroimaging analyses. Secondary endpoints evaluated changes from baseline in neuropsychological health using cognitive assessments, including the 11-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment, Clinical Dementia Rating, Quick Dementia Rating Scale, Alzheimer’s Disease Composite Score, and Global Rating of Change (GRC). Exploratory endpoints assessed changes from baseline in neuroinflammation biomarkers (tumor necrosis factor alpha, TNF-α) and AD (amyloid beta and phosphorylated tau [P-tau]). Results: NE3107 was associated with clinician-rated improvements in cerebral blood flow and functional connectivity within the brain. In patients with MMSE ≥ 20 (mild cognitive impairment to mild AD; n = 17), NE3107 was associated with directional, but statistically nonsignificant, changes in brain glutathione levels, along with statistically significant improvements in ADAS-Cog11 (P = .017), Clinical Dementia Rating (P = .042), Quick Dementia Rating Scale (P = .002), Alzheimer’s Disease Composite Score (P = .0094), and clinician-rated GRC (P < .001), as well as in cerebrospinal fluid P-tau levels (P = .034) and P-tau:amyloid beta 42 ratio (P = .04). Biomarker analyses also demonstrated directional, but statistically non-significant, changes in plasma TNF-α, consistent with the expected mechanism of NE3107. Importantly, we observed a statistically significant correlation (r = 0.59) between improvements in TNF-α levels and ADAS-Cog11 scores (P = .026) in patients with baseline MMSE ≥ 20. Conclusion: Our results indicate that in this study NE3107 was associated with what appear to be positive neurophysiological and neuropsychological findings, as well as evidence of improvement in biomarkers associated with neuroinflammation and AD in patients diagnosed with dementia. Our findings are consistent with previous preclinical and clinical observations and highlight a central role of neuroinflammation in AD pathogenesis.
- Open Access
- 18 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain
The blood–brain barrier (BBB) presents a significant challenge for targeted drug delivery. A proposed method to improve drug delivery across the BBB is focused ultrasound (fUS), which delivers ultrasound waves to a targeted location in the brain and is hypothesized to open the BBB. Furthermore, stem cell-derived exosomes have been suggested as a possible anti-inflammatory molecule that may have neural benefits, if able to pass the BBB. In the present study, transcranial low-intensity focused ultrasound (LIFU), without the use of intravenous microbubbles, was assessed for both (1) its ability to influence the BBB, as well as (2) its ability to increase the localization of intravenously administered small molecules to a specific region in the brain. In vivo rat studies were conducted with a rodent-customized 2 MHz LIFU probe (peak pressure = 1.5 MPa), and injection of labeled stem cell-derived exosomes. The results suggested that LIFU (without microbubbles) did not appear to open the BBB after exposure times of 20, 40, or 60 min; instead, there appeared to be an increase in transcytosis of the dextran tracer. Furthermore, the imaging results of the exosome study showed an increase in exosome localization in the right hippocampus following 60 min of targeted LIFU.
- 18 October 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Open AccessUse of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain
The blood–brain barrier (BBB) presents a significant challenge for targeted drug delivery. A proposed method to improve drug delivery across the BBB is focused ultrasound (fUS), which delivers ultrasound waves to a targeted location in the brain and is hypothesized to open the BBB. Furthermore, stem cell-derived exosomes have been suggested as a possible anti-inflammatory molecule that may have neural benefits, if able to pass the BBB. In the present study, transcranial low-intensity focused ultrasound (LIFU), without the use of intravenous microbubbles, was assessed for both (1) its ability to influence the BBB, as well as (2) its ability to increase the localization of intravenously administered small molecules to a specific region in the brain. In vivo rat studies were conducted with a rodent-customized 2 MHz LIFU probe (peak pressure = 1.5 MPa), and injection of labeled stem cell-derived exosomes. The results suggested that LIFU (without microbubbles) did not appear to open the BBB after exposure times of 20, 40, or 60 min; instead, there appeared to be an increase in transcytosis of the dextran tracer. Furthermore, the imaging results of the exosome study showed an increase in exosome localization in the right hippocampus following 60 min of targeted LIFU.
- Open Access
- 16 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (16) , 2690
Functional MRI Lateralization [M1] of dlPFC and Implications for Transcranial Magnetic Stimulation (TMS) Targeting
The present study investigates a potential method of optimizing effective strategies for the functional lateralization of the dorsolateral prefrontal cortex (dlPFC) while in a scanner. Effective hemisphere lateralization of the dlPFC is crucial for lowering the functional risks connected to specific interventions (such as neurosurgery and transcranial magnetic stimulation (TMS), as well as increasing the effectiveness of a given intervention by figuring out the optimal location. This task combines elements of creative problem solving, executive decision making based on an internal rule set, and working memory. A retrospective analysis was performed on a total of 58 unique participants (34 males, 24 females, Mage = 42.93 years, SDage = 16.38). Of these participants, 47 were classified as right-handed, 7 were classified as left-handed, and 4 were classified as ambidextrous, according to the Edinburgh Handedness Inventory. The imaging data were qualitatively judged by two trained, blinded investigators (neurologist and neuropsychologist) for dominant handedness (primary motor cortex) and dominant dorsolateral prefrontal cortex (dlPFC). The results demonstrated that 21.4% of right-handed individuals showed a dominant dlPFC localized to the right hemisphere rather than the assumed left, and 16.7% of left-handers were dominant in their left hemisphere. The task completed in the scanner might be an efficient method for localizing a potential dlPFC target for the purpose of brain stimulation (e.g., TMS), though further study replications are needed to extend and validate these findings.
- 16 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (16) , 2690
Open AccessFunctional MRI Lateralization [M1] of dlPFC and Implications for Transcranial Magnetic Stimulation (TMS) Targeting
The present study investigates a potential method of optimizing effective strategies for the functional lateralization of the dorsolateral prefrontal cortex (dlPFC) while in a scanner. Effective hemisphere lateralization of the dlPFC is crucial for lowering the functional risks connected to specific interventions (such as neurosurgery and transcranial magnetic stimulation (TMS), as well as increasing the effectiveness of a given intervention by figuring out the optimal location. This task combines elements of creative problem solving, executive decision making based on an internal rule set, and working memory. A retrospective analysis was performed on a total of 58 unique participants (34 males, 24 females, Mage = 42.93 years, SDage = 16.38). Of these participants, 47 were classified as right-handed, 7 were classified as left-handed, and 4 were classified as ambidextrous, according to the Edinburgh Handedness Inventory. The imaging data were qualitatively judged by two trained, blinded investigators (neurologist and neuropsychologist) for dominant handedness (primary motor cortex) and dominant dorsolateral prefrontal cortex (dlPFC). The results demonstrated that 21.4% of right-handed individuals showed a dominant dlPFC localized to the right hemisphere rather than the assumed left, and 16.7% of left-handers were dominant in their left hemisphere. The task completed in the scanner might be an efficient method for localizing a potential dlPFC target for the purpose of brain stimulation (e.g., TMS), though further study replications are needed to extend and validate these findings.
- Open Access
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 365-366
A pilot study of transcranial infrared laser stimulation for the treatment of traumatic brain injury
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 365-366
Open AccessA pilot study of transcranial infrared laser stimulation for the treatment of traumatic brain injury
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S6) , e054778
The effect of plasmalogen precursor supplementation on blood plasmalogen and C‐reactive protein levels and cognition in cognitively impaired persons
Background: Decreased blood and brain plasmalogens levels are associated with decreased cognition in humans. 1‐O‐alkyl‐2,3‐diacylglycerol (ADG) plasmalogen precursors containing docosahexaenoic acid (DHA) at the sn‐2 position have been shown to increase blood plasmalogens and to be neuroprotective in animal models of neurodegeneration. The goal of this study was to evaluate the effect of dietary DHA‐ADG supplementation on blood plasmalogen and C‐Reactive Protein (CRP) levels and cognition in cognitively impaired persons.Method: Twenty persons (9M/11F), aged 37‐81 (average = 68) with mild to moderate cognitive impairment [CDR: 13(0.5); 3(1); 4(2)] were administered an escalating dose of DHA‐ADG [1.0ml/day for 30 days; 2.0ml/day for 60 days; 4.0ml for 30 days]. Blood plasmalogen and CRP levels and cognitive status were measured at baseline and the end of each month. Cognitive status was determined using the Quick Dementia Rating System (QDRS), which was used to derive the participant’s Clinical Dementia Rating (CDR).Result: Overall, maximum average DHA ethanolamine plasmalogen levels were achieved by the end of the 2nd month [224% of baseline, 95%CI = 173‐273%] and this level of elevation was sustained for the duration of the study. Of the 20 participants, 14 (70%) exhibited robust and sustained plasmalogen elevations (>150%, >2 months, ADG Responder). Of the 14 ADG responders, 10 exhibited improvements on QDRS and 6 of these 10 exhibited improvements of at least one CDR level. Of the 14 ADG responders, 4 had baseline CRP levels >1.0. In each of these 4 subjects, CRP levels decreased by >0.5 by the end of the 4th month. DHA‐ADG was well tolerated at all dosages and no adverse reactions were observed. No cognitive improvement was observed in any of the ADG non‐responders.Conclusion: DHA‐ADG was effective at elevating blood plasmalogen levels at the dosages studied. 10/14 (71%) of cognitively impaired persons experienced improved levels of cognition when blood DHA‐plasmalogens were elevated by >150%. In all persons with elevated baseline CRP levels, DHA‐plasmalogen elevation was associated with a decrease in blood CRP. This analysis suggests that DHA‐ADG supplementation may be beneficial for patients with mild to moderate cognitive impairment.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S6) , e054778
The effect of plasmalogen precursor supplementation on blood plasmalogen and C‐reactive protein levels and cognition in cognitively impaired persons
Background: Decreased blood and brain plasmalogens levels are associated with decreased cognition in humans. 1‐O‐alkyl‐2,3‐diacylglycerol (ADG) plasmalogen precursors containing docosahexaenoic acid (DHA) at the sn‐2 position have been shown to increase blood plasmalogens and to be neuroprotective in animal models of neurodegeneration. The goal of this study was to evaluate the effect of dietary DHA‐ADG supplementation on blood plasmalogen and C‐Reactive Protein (CRP) levels and cognition in cognitively impaired persons.Method: Twenty persons (9M/11F), aged 37‐81 (average = 68) with mild to moderate cognitive impairment [CDR: 13(0.5); 3(1); 4(2)] were administered an escalating dose of DHA‐ADG [1.0ml/day for 30 days; 2.0ml/day for 60 days; 4.0ml for 30 days]. Blood plasmalogen and CRP levels and cognitive status were measured at baseline and the end of each month. Cognitive status was determined using the Quick Dementia Rating System (QDRS), which was used to derive the participant’s Clinical Dementia Rating (CDR).Result: Overall, maximum average DHA ethanolamine plasmalogen levels were achieved by the end of the 2nd month [224% of baseline, 95%CI = 173‐273%] and this level of elevation was sustained for the duration of the study. Of the 20 participants, 14 (70%) exhibited robust and sustained plasmalogen elevations (>150%, >2 months, ADG Responder). Of the 14 ADG responders, 10 exhibited improvements on QDRS and 6 of these 10 exhibited improvements of at least one CDR level. Of the 14 ADG responders, 4 had baseline CRP levels >1.0. In each of these 4 subjects, CRP levels decreased by >0.5 by the end of the 4th month. DHA‐ADG was well tolerated at all dosages and no adverse reactions were observed. No cognitive improvement was observed in any of the ADG non‐responders.Conclusion: DHA‐ADG was effective at elevating blood plasmalogen levels at the dosages studied. 10/14 (71%) of cognitively impaired persons experienced improved levels of cognition when blood DHA‐plasmalogens were elevated by >150%. In all persons with elevated baseline CRP levels, DHA‐plasmalogen elevation was associated with a decrease in blood CRP. This analysis suggests that DHA‐ADG supplementation may be beneficial for patients with mild to moderate cognitive impairment.
- Open Access
- 1 November 2021
- Published by Elsevier in Brain Stimulation
- Vol. 14 (6) , 1663
Investigation of focused ultrasound on blood-brain barrier permeability for small molecule delivery to the hippocampal formation: A preclinical investigation
- 1 November 2021
- Published by Elsevier in Brain Stimulation
- Vol. 14 (6) , 1663
Open AccessInvestigation of focused ultrasound on blood-brain barrier permeability for small molecule delivery to the hippocampal formation: A preclinical investigation
- Open Access
- 1 November 2021
- Published by Elsevier in Brain Stimulation
- Vol. 14 (6) , 1627
Comparing Therapeutic Focused Ultrasound (tfUS) in Conjunction with Bosutinib versus Independent tfUS Administration Among Alzheimer’s Patients
- 1 November 2021
- Published by Elsevier in Brain Stimulation
- Vol. 14 (6) , 1627
Open AccessComparing Therapeutic Focused Ultrasound (tfUS) in Conjunction with Bosutinib versus Independent tfUS Administration Among Alzheimer’s Patients
- Open Access
- 21 September 2021
- Published by Elsevier in Brain Stimulation
- Vol. 14 (6) , 1444-1446
A case of COVID-encephalopathy imaged with fMRI and treated with near infrared light
- 21 September 2021
- Published by Elsevier in Brain Stimulation
- Vol. 14 (6) , 1444-1446
Open AccessA case of COVID-encephalopathy imaged with fMRI and treated with near infrared light